<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131281">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02112877</url>
  </required_header>
  <id_info>
    <org_study_id>STE-HUM-004P</org_study_id>
    <nct_id>NCT02112877</nct_id>
  </id_info>
  <brief_title>VIRTUS: An Evaluation of the Veniti Vici™ Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow Obstruction</brief_title>
  <acronym>VIRTUS</acronym>
  <official_title>VIRTUS-OUS Safety and Efficacy of the Veniti Vici™ Venous Stent System (Veniti, Inc.) When Used to Treat Clinically Significant Chronic Non-malignant Obstruction of the Iliofemoral Venous Segment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veniti</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veniti</source>
  <oversight_info>
    <authority>Ireland: Irish Medicines Board</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, single arm, non-randomized study to evaluate safety and
      efficacy of the Veniti Vici™ Venous Stent System in relation to pre-defined Objective
      Performance goals.  The follow-up period is 36 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this prospective study is to assess the safety and efficacy of the Veniti
      Vici™ Venous Stent System in achieving patency of the target venous lesion through 36 months
      in patients with clinically significant chronic non-malignant obstruction of the iliofemoral
      venous outflow tract.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Major Adverse Events within 30 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>12 months post-intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary patency rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Venous Disorder</condition>
  <condition>Venous Outflow Obstruction</condition>
  <condition>Symptomatic Venous Outflow Obstruction of Iliofemoral Vein</condition>
  <arm_group>
    <arm_group_label>Veniti Vici™ Venous Stent System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Veniti Vici™ Venous Stent System</intervention_name>
    <arm_group_label>Veniti Vici™ Venous Stent System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Willing and capable of complying with all follow-up evaluations at the specified
             times

          -  Presence of unilateral, clinically significant, chronic non-malignant obstruction of
             the common femoral vein, external iliac vein, common iliac vein, or any combination
             thereof

          -  Patient willing and able to provide informed consent.

          -  Negative pregnancy test in females of child-bearing potential

        Exclusion Criteria:

          -  Presence or history of clinically significant pulmonary emboli within 6 months prior
             to enrollment.

          -  Venous obstruction that extends into the inferior vena cava (IVC)

          -  Contralateral disease of the common femoral vein, external iliac vein, common iliac
             vein, or any combination thereof with planned treatment within 30 days after subject
             enrollment

          -  Uncontrolled or active coagulopathy or known uncorrectable bleeding diathesis

          -  Uncorrected hemoglobin of ≤ 9 g/dL

          -  Intended concurrent thrombolysis or thrombectomy procedure OR intended or planned
             (within 30 days) adjuvant procedure such as creation of temporary arteriovenous
             fistula, placement of IVC filter, endovenectomy or saphenous vein ablation

          -  Patients who have had any prior surgical or endovascular procedure of the target
             vessel

          -  Patients in whom the lesions cannot be traversed with a guide wire.

          -  Female of childbearing potential who is pregnant or plans to become pregnant during
             the duration of the clinical study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Marston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmood Razavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vascular and Interventional Specialists of Orange County</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Galway University Hospitals</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Collette Kirwan</last_name>
      <phone>+353 91 494280</phone>
      <email>collette.kirwan@nuigalway.ie</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Daly</last_name>
      <phone>+353 91 495892</phone>
      <email>lisa.daly@nuigalway.ie</email>
    </contact_backup>
    <investigator>
      <last_name>Gerry O'Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Monteprincipe y Torrelodones</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Ramirez Ortega, MD</last_name>
      <phone>0034 619 20 79 22</phone>
      <email>ramirezortega75@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marta Ramirez Ortega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>April 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iliofemoral vein</keyword>
  <keyword>venous</keyword>
  <keyword>venous obstruction</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
